JP5444325B2 - 改善された機能性及び効能を有する自己崩壊性経皮治療システム - Google Patents
改善された機能性及び効能を有する自己崩壊性経皮治療システム Download PDFInfo
- Publication number
- JP5444325B2 JP5444325B2 JP2011502263A JP2011502263A JP5444325B2 JP 5444325 B2 JP5444325 B2 JP 5444325B2 JP 2011502263 A JP2011502263 A JP 2011502263A JP 2011502263 A JP2011502263 A JP 2011502263A JP 5444325 B2 JP5444325 B2 JP 5444325B2
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- disintegrating
- self
- therapeutic system
- transdermal therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 16
- 238000000926 separation method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000005553 drilling Methods 0.000 claims description 9
- 239000012286 potassium permanganate Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 229960001736 buprenorphine Drugs 0.000 claims description 5
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 229960002428 fentanyl Drugs 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001391 alfentanil Drugs 0.000 claims description 2
- 229960002069 diamorphine Drugs 0.000 claims description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 2
- 229960004739 sufentanil Drugs 0.000 claims description 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 13
- -1 for example Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229920006267 polyester film Polymers 0.000 description 5
- 244000027321 Lychnis chalcedonica Species 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013039 cover film Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- YADSGOSSYOOKMP-UHFFFAOYSA-N dioxolead Chemical compound O=[Pb]=O YADSGOSSYOOKMP-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- BXNHTSHTPBPRFX-UHFFFAOYSA-M potassium nitrite Chemical class [K+].[O-]N=O BXNHTSHTPBPRFX-UHFFFAOYSA-M 0.000 description 2
- 235000010289 potassium nitrite Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical class [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000002557 mineral fiber Substances 0.000 description 1
- 239000011490 mineral wool Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 150000002976 peresters Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/0075—Disposal of medical waste
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental & Geological Engineering (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
10/2003,42; Transdermal Controlled Systemic Medications, Y.W.Chien, Drugs and the Pharmaceutical Sciences, Vol.31; Polymers in Transdermal Drug Delivery Systems), S.Kandavilliet al., Pharmaceutical Technology, May 2002, 62-80)。
酢酸エチル、ヘプタン及びイソプロパノール/トルエンの有機溶媒混合物中のアクリル酸2−エチルヘキシル、酢酸ビニル、アクリル酸ブチル及びアクリル酸の単量体から成る自己架橋型ポリアクリレートの溶液(1.14g)に、レブリン酸(100g)、オレイン酸オレイル(150g)、ポリビニルピロリドン(100g)、エタノール(150g)、酢酸エチル(200g)及びブプレノルフィン塩基(100g)を加えた。この混合物を均一になるまで約2時間に亘って撹拌した。均一化後、混合物を、厚みが100μmのポリエステルフィルムのシリコン処理された面に塗布し、その後、乾燥室において70℃で10分間、乾燥することによって溶媒を除去した。コーティングにおける被覆厚みは、溶媒の除去で単位面積当たりの質量が約80g/m2になるように選択された。溶媒の除去に続いて、シリコン処理されたポリエステルフィルム及び活性成分を含有するポリマー層から構成される積層体が、第二のより弱くシリコン処理されたポリエステルフィルムで裏打ちされた。その後、得られた積層体を、5×5cmの辺長さを有する四角形に切断した。次いで、この5×5cmのシリコン処理されたポリエステルフィルムを、積層体の側面上で除去して、例えば4×4cmのサイズの吸水性の液透過性材料、例えば不織布を中央部に接着させた。次いで、粉末形態の過マンガン酸カリウムを充填した、エンボス加工の縁部を備えた濾紙パウチを、吸収性の液透過性材料上に置いた:ここでパウチのデザインは、その全面積が、活性成分を含有するポリマー層の面積よりも小さくなるようなものであった。
上部カバー層と、過マンガン酸カリウムを粉末形態で有するパウチとの間に、全ての周辺がシールされ、マルタ十字架及び1.5ミリリッターの水で充たされた液密パウチを、中に結合させた点が異なることを除いて、実施例1が繰り返された。使用したTTSを患者の皮膚から除去する際に、マルタ十字架の少なくとも一点が液体パウチの下方壁を突き刺し、その結果水の排出をもたらし、これがその下に配列された過マンガン酸カリウムと直ちに接触を始める。
Claims (13)
- 少なくとも一つの活性成分を含む層;
活性成分と活性成分を無用にする薬剤の間の分離を達成する層であって、液体に対し透過性であるが、固体に対して不透過性である層;
固体の形態又はペーストの形態の、活性成分を無用にする少なくとも一つの薬剤を含む層;
液体に対し不透過性である層;及び
鈍い外形及び鋭い又は尖った内部領域を有する、少なくとも一つの隣接層を穿孔するための少なくとも一つの機械的手段であって、前記外形及び領域により、移動相を、活性成分を無用にする薬剤に接近させることができ、このようにして活性成分、及び活性成分を無用にする薬剤を互いに接触させ、そして活性成分をこの接触によって破壊させることを確実にすることによって、使用後のTTSを除去する際に、活性成分、及び活性成分を無用にする薬剤の間の分離の解消をもたらす前記穿孔のための手段;
をこの順で含む、自己崩壊性経皮治療システム(TTS)。 - 経皮パッチであることを特徴とする、請求項1に記載の自己崩壊性経皮治療システム。
- 患者の皮膚からのTTSの除去に続いて、活性成分、及び活性成分を無用にする薬剤を、移動相の存在下で互いに化学的に反応させることを特徴とする、請求項1又は2に記載の自己崩壊性経皮治療システム。
- 活性成分が鎮痛剤又は麻薬であることを特徴とする、請求項1〜3の何れか1項に記載の自己崩壊性経皮治療システム。
- 活性成分がモルヒネ誘導体、ヘロイン又はブプレノルフィンであることを特徴とする、請求項1〜4の何れか1項に記載の自己崩壊性経皮治療システム。
- 活性成分がフェンタニル、スフェンタニル又はアルフェンタニルであることを特徴とする、請求項1〜5の何れか1項に記載の自己崩壊性経皮治療システム。
- 活性成分を無用にする薬剤が酸化剤であることを特徴とする、請求項1〜6の何れか1項に記載の自己崩壊性経皮治療システム。
- 活性成分を無用にする薬剤が過マンガン酸カリウムであることを特徴とする、請求項1〜7の何れか1項に記載の自己崩壊性経皮治療システム。
- 移動相が水であることを特徴とする、請求項1〜8の何れか1項に記載の自己崩壊性経皮治療システム。
- 穿孔のための機械的手段が多数の鋭い又は尖った領域を有することを特徴とする、請求項1〜9の何れか1項に記載の自己崩壊性経皮治療システム。
- 穿孔のための機械的手段が星形形状を有することを特徴とする、請求項1〜10の何れか1項に記載の自己崩壊性経皮治療システム。
- 穿孔のための機械的手段に関して、皮膚からTTSを除去する際に、その構造の捻じ曲げによって、内部領域において対応して配置された少なくとも一つの点を、その形状によって決められる旋回軸回りに、隣接層の方向に面から最大90度までの角度で回転し、このようにして少なくとも一つの隣接層の穿孔を行なうことを特徴とする、請求項1に記載の自己崩壊性経皮治療システム。
- 疼痛の治療に使用するための、請求項1〜12の何れか1項に記載の自己崩壊性経皮治療システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008016804A DE102008016804B4 (de) | 2008-04-02 | 2008-04-02 | Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung |
DE102008016804.1 | 2008-04-02 | ||
PCT/EP2009/002205 WO2009121514A2 (de) | 2008-04-02 | 2009-03-26 | Selbstzerstörendes transdermales therapeutisches system mit verbesserter funktionalität und wirksamkeit |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011516439A JP2011516439A (ja) | 2011-05-26 |
JP5444325B2 true JP5444325B2 (ja) | 2014-03-19 |
Family
ID=40792688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502263A Expired - Fee Related JP5444325B2 (ja) | 2008-04-02 | 2009-03-26 | 改善された機能性及び効能を有する自己崩壊性経皮治療システム |
Country Status (16)
Country | Link |
---|---|
US (2) | US8435219B2 (ja) |
EP (1) | EP2276477B1 (ja) |
JP (1) | JP5444325B2 (ja) |
KR (1) | KR101621569B1 (ja) |
CN (1) | CN101980703B (ja) |
AU (1) | AU2009231149B2 (ja) |
BR (1) | BRPI0911267A2 (ja) |
CA (1) | CA2720400C (ja) |
DE (1) | DE102008016804B4 (ja) |
ES (1) | ES2688185T3 (ja) |
IL (1) | IL208261A (ja) |
MX (1) | MX2010010916A (ja) |
NZ (1) | NZ587998A (ja) |
RU (1) | RU2506948C2 (ja) |
WO (1) | WO2009121514A2 (ja) |
ZA (1) | ZA201006616B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009036485B4 (de) | 2009-08-07 | 2012-10-04 | Lts Lohmann Therapie-Systeme Ag | Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen |
US8591488B2 (en) | 2012-01-31 | 2013-11-26 | Butterfly Health, Inc. | Devices and methods for treating accidental bowel leakage |
USD720848S1 (en) | 2012-05-21 | 2015-01-06 | Butterfly Health, Inc. | Body liner for anal leakage |
USD721170S1 (en) | 2012-11-16 | 2015-01-13 | Butterfly Health, Inc. | Body liner for anal leakage |
CN104815833B (zh) * | 2015-04-17 | 2017-05-24 | 娄文忠 | 一种用于非易失性存储芯片的自毁微系统及其自毁方法 |
EP3405179B1 (de) | 2016-01-20 | 2023-08-09 | LTS Lohmann Therapie-Systeme AG | Steuerung der freisetzung von wasser aus einer formfesten wasserhaltigen zusammensetzung |
US10779816B2 (en) * | 2016-07-07 | 2020-09-22 | Medline Industries, Inc. | Orthopedic implant, method, and kit |
GB201616223D0 (en) * | 2016-09-23 | 2016-11-09 | University College Cardiff Consultants Limited | Topical treatment patch |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4917676A (en) * | 1986-11-20 | 1990-04-17 | Ciba-Geigy Corporation | User-activated transdermal therapeutic system |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
JP4219172B2 (ja) * | 2001-04-23 | 2009-02-04 | ユーロ−セルティーク エス・エイ | 経皮的投与成形体の処置システム |
ES2377672T3 (es) * | 2001-05-01 | 2012-03-29 | Euro-Celtique S.A. | Sistemas transdérmicos resistentes al abuso que contienen opioides |
DE10141651B4 (de) * | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
US20050112068A1 (en) * | 2003-10-28 | 2005-05-26 | Warner Kevin S. | Systems and methods for reducing unintended use of active ingredients in dermal delivery devices |
US7867511B2 (en) * | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
CA2613122C (en) | 2005-06-29 | 2013-01-22 | Compumedics Limited | Sensor assembly with conductive bridge |
US7740879B2 (en) * | 2006-01-17 | 2010-06-22 | Harrogate Holdings | Abuse resistant transdermal drug delivery patch |
DE102006025282A1 (de) | 2006-05-31 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Selbstzerstörendes transdermales therapeutisches System |
US7838715B2 (en) * | 2009-01-21 | 2010-11-23 | Palo Alto Research Center Incorporated | Drug deactivation system and method of deactivating a drug using the same |
-
2008
- 2008-04-02 DE DE102008016804A patent/DE102008016804B4/de not_active Expired - Fee Related
-
2009
- 2009-03-26 AU AU2009231149A patent/AU2009231149B2/en not_active Ceased
- 2009-03-26 BR BRPI0911267A patent/BRPI0911267A2/pt not_active IP Right Cessation
- 2009-03-26 ES ES09726650.6T patent/ES2688185T3/es active Active
- 2009-03-26 NZ NZ587998A patent/NZ587998A/en not_active IP Right Cessation
- 2009-03-26 KR KR1020107021859A patent/KR101621569B1/ko active IP Right Grant
- 2009-03-26 WO PCT/EP2009/002205 patent/WO2009121514A2/de active Application Filing
- 2009-03-26 JP JP2011502263A patent/JP5444325B2/ja not_active Expired - Fee Related
- 2009-03-26 CA CA2720400A patent/CA2720400C/en not_active Expired - Fee Related
- 2009-03-26 EP EP09726650.6A patent/EP2276477B1/de active Active
- 2009-03-26 US US12/935,085 patent/US8435219B2/en active Active
- 2009-03-26 MX MX2010010916A patent/MX2010010916A/es active IP Right Grant
- 2009-03-26 CN CN2009801115917A patent/CN101980703B/zh not_active Expired - Fee Related
- 2009-03-26 RU RU2010140102/14A patent/RU2506948C2/ru not_active IP Right Cessation
-
2010
- 2010-09-15 ZA ZA2010/06616A patent/ZA201006616B/en unknown
- 2010-09-20 IL IL208261A patent/IL208261A/en not_active IP Right Cessation
-
2013
- 2013-03-27 US US13/851,575 patent/US8894621B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009121514A3 (de) | 2010-06-10 |
US20110022009A1 (en) | 2011-01-27 |
AU2009231149A1 (en) | 2009-10-08 |
CN101980703B (zh) | 2012-10-17 |
CA2720400C (en) | 2016-08-16 |
CN101980703A (zh) | 2011-02-23 |
RU2506948C2 (ru) | 2014-02-20 |
KR20100135244A (ko) | 2010-12-24 |
KR101621569B1 (ko) | 2016-05-16 |
RU2010140102A (ru) | 2012-04-10 |
ES2688185T3 (es) | 2018-10-31 |
WO2009121514A2 (de) | 2009-10-08 |
US20130226108A1 (en) | 2013-08-29 |
MX2010010916A (es) | 2010-11-05 |
IL208261A0 (en) | 2010-12-30 |
IL208261A (en) | 2015-09-24 |
BRPI0911267A2 (pt) | 2015-09-29 |
AU2009231149B2 (en) | 2014-01-23 |
US8435219B2 (en) | 2013-05-07 |
JP2011516439A (ja) | 2011-05-26 |
NZ587998A (en) | 2012-06-29 |
DE102008016804A1 (de) | 2009-10-08 |
CA2720400A1 (en) | 2009-10-08 |
ZA201006616B (en) | 2011-05-25 |
EP2276477A2 (de) | 2011-01-26 |
EP2276477B1 (de) | 2018-08-15 |
DE102008016804B4 (de) | 2012-01-05 |
US8894621B2 (en) | 2014-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5444325B2 (ja) | 改善された機能性及び効能を有する自己崩壊性経皮治療システム | |
US20090035357A1 (en) | Method of drug delivery using a transdermal device having a phase change material | |
AU2007267464B2 (en) | Autodestructive transdermal therapeutic system | |
JP6125556B2 (ja) | 経皮治療システム中の医療用活性成分の破壊的処理 | |
US20230381116A1 (en) | Controlling water release from a dimensionally stable aqueous composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131220 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5444325 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |